DENTSPLY SIRONA (XRAY) Projected to Post Quarterly Earnings on Thursday

DENTSPLY SIRONA (NASDAQ:XRAY) is expected to issue its Q3 2026 results after the market closes on Thursday, November 5th. Analysts expect DENTSPLY SIRONA to announce earnings of $0.3088 per share and revenue of $861.68 million for the quarter. DENTSPLY SIRONA has set its FY 2026 guidance at 1.400-1.500 EPS. Individuals may visit the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Thursday, November 5, 2026 at 4:30 PM ET.

DENTSPLY SIRONA (NASDAQ:XRAY) last posted its quarterly earnings data on Thursday, August 6th. The medical instruments supplier reported $0.52 earnings per share for the quarter, topping analysts’ consensus estimates of $0.35 by $0.17. DENTSPLY SIRONA had a negative net margin of 14.99% and a positive return on equity of 20.84%. The company had revenue of $898.00 million during the quarter, compared to analysts’ expectations of $889.93 million. During the same period in the prior year, the business posted $0.52 earnings per share. The firm’s revenue for the quarter was down 4.1% on a year-over-year basis. On average, analysts expect DENTSPLY SIRONA to post $1.39 EPS for the current fiscal year and $1.48 EPS for the next fiscal year.

DENTSPLY SIRONA Stock Down 0.8%

Shares of NASDAQ XRAY opened at $9.82 on Tuesday. The company’s 50-day simple moving average is $9.68 and its 200-day simple moving average is $11.33. DENTSPLY SIRONA has a 52-week low of $8.32 and a 52-week high of $14.76. The firm has a market cap of $1.96 billion, a price-to-earnings ratio of -3.57, a price-to-earnings-growth ratio of 1.21 and a beta of 0.87. The company has a quick ratio of 1.07, a current ratio of 1.63 and a debt-to-equity ratio of 1.48.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on the stock. Barclays raised their price target on shares of DENTSPLY SIRONA from $9.00 to $11.00 and gave the company an “underweight” rating in a research note on Monday, August 24th. BMO Capital Markets cut their price objective on DENTSPLY SIRONA from $13.00 to $10.00 and set a “market perform” rating for the company in a research note on Thursday, September 17th. Leerink Partners reduced their target price on DENTSPLY SIRONA from $14.00 to $10.00 and set a “market perform” rating for the company in a report on Wednesday, October 14th. Mizuho reduced their target price on DENTSPLY SIRONA from $14.00 to $12.00 and set a “neutral” rating for the company in a report on Thursday, October 22nd. Finally, Piper Sandler decreased their target price on DENTSPLY SIRONA from $14.00 to $12.00 and set a “neutral” rating on the stock in a research report on Friday, October 9th. Three equities research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and three have given a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $12.62.

About DENTSPLY SIRONA

DENTSPLY SIRONA is a global manufacturer of professional dental products and technologies. The company serves dentists, dental specialists, dental laboratories and other oral health professionals with solutions used in preventive, restorative, prosthetic, endodontic and implant dentistry.

Its portfolio includes dental equipment, imaging and treatment systems, CAD/CAM technology, consumable dental materials, orthodontic products, endodontic instruments and solutions, dental implants, prosthetic components and laboratory products.